

AB GLOBAL DEVELOPED HEALTH CARE

31 October 2024

INVESTMENT OBJECTIVE

The investment objective of the Fund is to outperform the Solactive Developed Markets Broad Health Care EUR Index NTR (SDMBHCEN) (the "Benchmark Index") over a long-term horizon by exploiting investment opportunities on the equity markets. The Benchmark Index is a broad liquid equity index (approximately 840 stocks) which intends to track the performance of Health Care companies from the Developed Markets within the Solactive Global Benchmark Series and the Solactive United States Benchmark Series. The Fund is actively managed, the equity exposure may significantly deviate from the components of the Benchmark Index. The fund is article 8 of SFDR.

Within the Investment Universe, equities composing the Portfolio will be selected by the Investment Manager, according to their ESG scoring, based on a best-in-class approach. Equities of the Investment Universe will be ranked using proprietary ESG materiality weightings, and a combination of fundamental ESG scores and third-party ESG management assessments; the Investment Manager's ESG research is used to determine ESG risk factor scores. The selection of equities composing the portfolio is achieved by excluding at least 20% of the stocks comprising the investment universe with the lowest rating. More than 90% of the equities composing the Portfolio do benefit from an ESG rating. The Portfolio will be rebalanced monthly respecting the methodology. However, the Management Company may decide to rebalance the Portfolio at any time at its discretion (the "Rebalancing Date"). The exposure of the Fund to equities through the Portfolio may vary between 0% and 150% on a weekly basis at least. As a result, the exposure may drift between such adjustments.

The Fund distributes a fixed dividend of EUR 5 per fund unit per year, divided into 12 identical monthly payments.

PERFORMANCE SINCE INCEPTION

DUE TO MIFID II REGULATION, FUND PERFORMANCES ARE NOT DISPLAYED IN THIS DOCUMENT.

Performance	MTD	YTD	3 Months	6 Months	1 Year	3 Years	Since inception
AB GLOBAL DEVELOPED HEALTH CARE Class I (EUR)	-	-	-	-	-	-	-
SOLACTIVE DEVELOPED	-2.18%	5.58%	-2.93%	3.82%	-	-	5.58%

PAST PERFORMANCE DOES NOT REFLECT FUTURE PERFORMANCE

The performance of AB GLOBAL DEVELOPED HEALTH CARE above is the NAV of Class I plus dividend, to be consistent with the Solactive Developed Index, which is being shown as 'dividends reinvested'.

5 best performing	Allocation	Perf. MTD*	Perf. YTD*	Contr. MTD	Contr. YTD
PENUMBRA INC	1.82%	20.89%	11.21%	0.52%	0.78%
GILEAD SCIENCES INC	3.58%	8.73%	34.46%	-0.12%	0.43%
UNITED THERAPEUTICS CORP	3.45%	7.11%	54.80%	-0.24%	2.19%
WEST PHARMACEUTICAL SERVICES	2.74%	5.29%	-19.87%	0.17%	3.90%
INTUITIVE SURGICAL INC	3.60%	5.26%	32.61%	-0.02%	0.52%

*Performances are calculated in portfolio currency

5 worst performing	Allocation	Perf. MTD*	Perf. YTD*	Contr. MTD	Contr. YTD
ELEVANCE HEALTH INC	2.85%	-19.91%	-23.77%	-0.71%	-0.94%
REGENERON PHARMACEUTICALS	2.86%	-18.17%	-8.04%	-0.55%	-0.53%
STRAUMANN HOLDING AG-REG	0.60%	-17.40%	-12.34%	0.77%	-0.71%
IDEXX LABORATORIES INC	2.17%	-17.34%	-16.47%	-0.55%	-1.53%
ALIGN TECHNOLOGY INC	0.99%	-17.26%	-33.27%	-0.71%	-0.35%

*Performances are calculated in portfolio currency

CHARACTERISTICS

Legal structure

SICAV

Class

I

Currency

EUR

Inception date of the share class

18th April 2024

Dividend

Distribution

Management company

SG 29 HAUSSMANN
(Groupe SOCIETE GENERALE)

Custodian

SOCIETE GENERALE LUXEMBOURG

ISIN

LU2744488573

Minimum deposit

EUR 1000

Minimum followup deposit

-

Issue fee/Exit fee

Up to 5% / Up to 1%

Management fee

0,93%

Performance fee

-

Liquidity

Daily

KEY FACTS

Fund volume (M EUR)

19.72 Mio. EUR

Performance annualized*

-

Leverage

1.34

All performances are calculated on the basis of official net asset values net of fees.

*Since inception

RISK INDICATORS


	Since inception
	Class*
Volatility	14.71%
Sharpe Ratio	-0.10
Maximum Drawdown	-10.80%
Beta	1.15

*Since inception


MONTHLY PERFORMANCES OF THE FUND

DUE TO MIFID II REGULATION, FUND PERFORMANCES ARE NOT DISPLAYED IN THIS DOCUMENT.


SECTOR ALLOCATION




GEOGRAPHIC ALLOCATION



MONTHLY CONTRIBUTIONS PER SECTOR



MONTHLY CONTRIBUTIONS PER REGION



MONTHLY COMMENT

Markets in October were roiled mainly by geopolitical tensions, but with strong economic performance in the background.

The escalating conflict in the Middle East has had a major impact on energy price volatility, raising investors' fears of renewed inflation, a sign that the difficulties of the past three years will continue. Nevertheless, the published statistics were reassuring, suggesting that these concerns will be addressed in the medium term. The clear trend toward the election of Donald Trump as US President has weighed on the bond market, with long rates soaring in anticipation of the fiscal loosening he would implement if elected.

Non-tech companies have reported excellent results, confirming their successful adaptation in a challenging environment and successful repositioning in the standardization of this environment.

After the US election, markets may experience some short-term volatility while analyzing the impact of the nominee's policies. But the Fed should independently continue its interest-rate normalization program and, barring further escalation of geopolitical conflicts, the market should return to its stable path.

DISCLAIMER

This document has been prepared for informational purposes only and has no contractual value. It is not intended to provide investment advice or any other investment service and does not constitute an offer, or a solicitation of an offer, to buy or sell any financial instrument or service. It does not constitute legal, accounting or tax advice. The information presented in this document is based on market data at a given moment and may change without prior notice. Past performances do not guarantee future results. Before any subscription of the product referred to in this document, the investor must read all the information contained in the regulatory documentation of the product, available on request from his advisor and SG 29 Haussmann and available, if applicable, on the SG 29 Haussmann website <https://sg29haussmann.societegenerale.fr/en/>. In particular, we invite you to take note of the risk factors specific to the product. This product may be subject to restrictions with regard to certain persons or in certain countries under national regulations applicable to said persons or in said countries. You should ensure that you are authorized to subscribe to this product. The potential investor must also ensure that the product is compatible with its financial situation, investment objectives, knowledge and experience in financial instruments, its degree of acceptance of the risk and its ability to bear the risk losses. SG 29 HAUSSMANN may not be held responsible for transactions effected on the basis of this document's content. This document has been issued by SG 29 HAUSSMANN. It may not be communicated and may not be reproduced in whole or in part, to a third party (except your own adviser subject to confidentiality obligation) without SG 29 HAUSSMANN's prior written consent. SG 29 Haussmann., a portfolio management company approved by the French Financial Markets Authority under number GP 06000029, S.A.S with a capital of € 2,000,000, headquartered in PARIS, 29 Boulevard Haussmann, registered in the Paris Trade and Companies Register under number B 450 777 008. Further details are available on the SG 29 Haussmann website: <https://sg29haussmann.societegenerale.fr/en/>.